Evidence map›Paper›PMID 28435308›Full record

ArticlePharmacogenomics and personalized medicine2017

Association of the

Patricia C Salgado, Fabiana Dv Genvigir, Claudia R Felipe, Helio Tedesco-Silva, Jose O Medina-Pestana, Sonia Q Doi, Mario H Hirata, Rosario Dc Hirata

Abstract read
In one paragraph

Article in Pharmacogenomics and personalized medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Patricia C SalgadoDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of Sao Paulo.
Fabiana Dv GenvigirDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of Sao Paulo.
Claudia R FelipeDivision of Nephrology, Hospital do Rim, Federal University of Sao Paulo, Sao Paulo, Brazil.
Helio Tedesco-SilvaDivision of Nephrology, Hospital do Rim, Federal University of Sao Paulo, Sao Paulo, Brazil.
Jose O Medina-PestanaDivision of Nephrology, Hospital do Rim, Federal University of Sao Paulo, Sao Paulo, Brazil.
Sonia Q DoiSchool of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Mario H HirataDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of Sao Paulo.
Rosario Dc HirataDepartment of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of Sao Paulo.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effects of genetic variants related to the pharmacodynamic mechanisms of immunosuppressive drugs on their therapeutic efficacy and safety have been poorly explored. This study was performed to investigate the influence of the PATIENTS AND

methodsA total of 148 Brazilian patients received tacrolimus (TAC)-based immunosuppressive therapy for 90 days post-kidney transplantation. The

resultsThe

conclusionThe

Indexed as

adverse eventsBrazilian patientskidney transplantationpolymorphismPPP3CAtacrolimus

Identifiers

PMID28435308
PMCPMC5386607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.